Project Grant R21CA302974
Award Date 7/1/26
Completion Date 6/30/28
Dollars Obligated $415K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Methodist Hospital Research Institute a $403,485 Project Grant effective September 1, 2025, through August 31, 2027, under the Cancer Treatment Research program (CFDA 93.395). The research project focuses on the development of novel platinum-based polymers designed to induce robust reactive oxygen species (ROS) production with tumor-specific toxicity, specifically targeting triple negative breast cancer (TNBC). The...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Methodist Hospital Research Institute a $415,257 Project Grant on June 9, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an image-guided, adaptable chimeric antigen receptor (CAR) T cell therapy system for solid tumors. The project, scheduled for completion by July 31, 2027, addresses critical limitations in current CAR T cell treatments, including tumor relapse,...
- Federal Project Grant Award Summary The National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) awarded a $164,000 Project Grant to The University of Texas MD Anderson Cancer Center, effective September 1, 2025, through August 31, 2027. This award supports research investigating the clonal determinants of platinum/PARP inhibitor (PARPi) cross-resistance in high-grade serous ovarian cancer (HGSOC). The research utilizes a novel somatic mosaic genetically-engineered mouse model...
- Federal Grant Award Summary Award Details: The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a $696,221 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 22, 2026, with a completion date of May 31, 2031. The award supports research to develop and evaluate improved methods of cancer treatment through fundamental and applied laboratory and clinical research. Products and Services: This grant funds research to reprogram virus-primed...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The Defense Health Agency awarded The Methodist Hospital Research Institute a $646,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective August 1, 2025, through July 31, 2027. The project, "Reprogramming Protumoral Neutrophils to Enhance Immune Checkpoint Inhibitor (ICI)-Based Responses in Bladder Cancer," supports translational research aimed at improving cancer immunotherapy outcomes for military-relevant...
- Federal Grant Award Summary The National Cancer Institute awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant totaling $433,256 under the Cancer Treatment Research program (CFDA 93.395) for the period June 1, 2026 through May 31, 2028. The research focuses on fragment-based targeting of epithelial-to-mesenchymal transition (EMT)-mediated resistance in epidermal growth factor receptor (EGFR)-mutant lung cancer. The project utilizes fragment-like chemical...
- Federal Project Grant Summary The National Cancer Institute (NCI) awarded The University of Texas MD Anderson Cancer Center a $653,967 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective March 16, 2026, through February 28, 2031. This research initiative focuses on investigating the mechanistic basis and developing therapeutic strategies for PPP2R1A mutations in gynecological cancers, specifically uterine serous endometrial carcinoma and ovarian clear cell...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant of $433,256 under the Cancer Treatment Research program (CFDA 93.395) for the period of September 1, 2025 through August 31, 2027. This award supports exploratory research into the role of antisense ribonucleic acids (asRNAs) in melanoma development and transformation. The project will deliver scientific research and analysis focused on...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $421,685 project grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded August 1, 2025, with a completion date of July 31, 2027. This award supports research investigating the LIFR-LCN2 pathway as a novel mechanism of immune suppression in hepatocellular carcinoma (HCC). The research aims to elucidate how loss of LIFR upregulates LCN2, leading to...